<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806232</url>
  </required_header>
  <id_info>
    <org_study_id>200661-0005</org_study_id>
    <nct_id>NCT02806232</nct_id>
  </id_info>
  <brief_title>An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)</brief_title>
  <official_title>Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase II study consisted of two parts, part 1 is open label, randomized, controlled and
      exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni.
      Part 2 investigated efficacy and safety with the selected formulation and dosage in S.
      mansoni infected children aged between 3 months - 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2016</start_date>
  <completion_date type="Actual">November 17, 2018</completion_date>
  <primary_completion_date type="Actual">October 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Cure Determined by Kato-Katz Method</measure>
    <time_frame>14-21 days post treatment</time_frame>
    <description>Clinical cure was defined as zero egg counts at 14-21 days post treatment as determined by the Kato-Katz method. Number of participants with clinical cure were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Egg Reduction Rate (Percent)</measure>
    <time_frame>Baseline, 14-21 days post treatment</time_frame>
    <description>Percent reduction in egg count was calculated as geometric mean egg count at post-treatment minus geometric mean egg count at baseline (before treatment) divided by geometric mean egg count at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Cure Determined by Point-of-Care Circulating Cathodic Antigen (POC-CCA) Test</measure>
    <time_frame>Day 2, Day 8 and 14-21 days post treatment</time_frame>
    <description>Clinical Cure defined as no parasite eggs in the stools as assessed by the commercially available POC-CCA assay for S. mansoni. Number of participants with clinical cure were reported.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">444</enrollment>
  <condition>Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biltricide (racemate praziquantel) oral tablets</intervention_name>
    <description>Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.</description>
    <arm_group_label>Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg</arm_group_label>
    <arm_group_label>Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racemate Praziquantel ODT</intervention_name>
    <description>Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.</description>
    <arm_group_label>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</arm_group_label>
    <arm_group_label>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levo Praziquantel ODT</intervention_name>
    <description>Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.</description>
    <arm_group_label>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</arm_group_label>
    <arm_group_label>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</arm_group_label>
    <arm_group_label>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</arm_group_label>
    <arm_group_label>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</arm_group_label>
    <arm_group_label>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female children aged 2 to 6 years (Part 1) and 3 to 24 months (Part 2)

          -  S. mansoni positive diagnosis defined as positive egg counts in stool (greater than
             [&gt;]1 egg/1 occasion) according to World Health Organization (WHO) classification :
             light (1-99 eggs per gram of faeces), moderate (100-399 eggs per gram of faeces) and
             heavy (greater than or equal to [&gt;=]400 eggs per gram of faeces) infections

          -  Minimum weight of 8.0 kg in 2- to 6-year-old children and of 4.0 kg in 3- to 24-month
             infants

             â€¢ Parents/legal representative ability to communicate well with the Investigator, to
             understand the protocol requirements and restrictions, and willing their children to
             comply with the requirements of the entire trial, i.e.

          -  To be examined by a study physician at screening and 14-21 days after treatment

          -  To provide stool and urine samples at screening, 24 hours and 8 days after treatment,
             as well as 14-21 days after treatment

          -  To provide finger prick blood samples for Pharmacokinetics (PK) studies and blood
             samples for safety assessments

        Exclusion Criteria:

          -  Treatment in the 4 weeks prior to study screening with Praziquantel (PZQ) , other
             anti-helminthic, antimalarial or anti-retroviral compounds or any other medication
             that might affect the PK of PZQ such as certain antiepileptics (e.g., carbamazepine or
             phenytoin), glucocorticosteroids (e.g., dexamethasone), chloroquine, rifampicin or
             cimetidine

          -  For children being breast fed, treatment of the mothers/wet nurses with PZQ in the 3
             days prior to administration of Investigational medicinal product

          -  Previous history of adverse reactions associated with PZQ treatment

          -  Marked increases of the liver transaminases (alanine aminotransferase and/or aspartate
             aminotransferase) above 3x Upper Limit of Normal (ULN)

          -  History of acute or severe chronic disease including hepato-splenic schistosomiasis

          -  Fever defined as temperature above 38.0 degree centigrade

          -  Debilitating illnesses such as tuberculosis, malnutrition, etc. as well as a medical
             history of seizures

          -  Mixed S. haematobium and S. mansoni infections

          -  Findings in the clinical examination of schistosome-infected children participating in
             the study as performed by the study clinician on the treatment day, that in the
             opinion of the Investigator constitutes a risk or a contraindication for the
             participation of the subject in the study or that could interfere with the study
             objectives, conduct or evaluation

          -  Unlikelihood to comply with the protocol requirements, instructions and trial-related
             restrictions, e.g., uncooperative attitude, inability to return for follow-up visits,
             and improbability of completing the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please Contact the Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <results_first_submitted>October 30, 2019</results_first_submitted>
  <results_first_submitted_qc>October 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2019</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Praziquantel ODT formulation</keyword>
  <keyword>Biltricide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02806232/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02806232/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg</title>
          <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg</title>
          <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</title>
          <description>Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</title>
          <description>Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</title>
          <description>Participants aged 13-24 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
        </group>
        <group group_id="P9">
          <title>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</title>
          <description>Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="60"/>
                <participants group_id="P7" count="60"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="58"/>
                <participants group_id="P6" count="58"/>
                <participants group_id="P7" count="60"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who were exposed to investigative medicinal product.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg</title>
          <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg</title>
          <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</title>
          <description>Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</title>
          <description>Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</title>
          <description>Participants aged 13-24 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
        </group>
        <group group_id="B9">
          <title>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</title>
          <description>Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="60"/>
            <count group_id="B5" value="60"/>
            <count group_id="B6" value="60"/>
            <count group_id="B7" value="60"/>
            <count group_id="B8" value="20"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="444"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="1.3"/>
                    <measurement group_id="B2" value="4.3" spread="1.3"/>
                    <measurement group_id="B3" value="4.4" spread="1.2"/>
                    <measurement group_id="B4" value="4.2" spread="1.2"/>
                    <measurement group_id="B5" value="4.2" spread="1.2"/>
                    <measurement group_id="B6" value="4.3" spread="1.1"/>
                    <measurement group_id="B7" value="4.4" spread="1.3"/>
                    <measurement group_id="B8" value="1.7" spread="0.3"/>
                    <measurement group_id="B9" value="0.6" spread="0.2"/>
                    <measurement group_id="B10" value="4.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="60"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="444"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Cure Determined by Kato-Katz Method</title>
        <description>Clinical cure was defined as zero egg counts at 14-21 days post treatment as determined by the Kato-Katz method. Number of participants with clinical cure were reported.</description>
        <time_frame>14-21 days post treatment</time_frame>
        <population>Modified intention-to-treat (mITT) analysis set included all participants who had a baseline measurement for the efficacy variable and did not use anti-malaria treatment after study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg</title>
            <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg</title>
            <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</title>
            <description>Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</title>
            <description>Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</title>
            <description>Participants aged 13-24 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
          </group>
          <group group_id="O9">
            <title>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</title>
            <description>Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Cure Determined by Kato-Katz Method</title>
          <description>Clinical cure was defined as zero egg counts at 14-21 days post treatment as determined by the Kato-Katz method. Number of participants with clinical cure were reported.</description>
          <population>Modified intention-to-treat (mITT) analysis set included all participants who had a baseline measurement for the efficacy variable and did not use anti-malaria treatment after study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="52"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Egg Reduction Rate (Percent)</title>
        <description>Percent reduction in egg count was calculated as geometric mean egg count at post-treatment minus geometric mean egg count at baseline (before treatment) divided by geometric mean egg count at baseline.</description>
        <time_frame>Baseline, 14-21 days post treatment</time_frame>
        <population>mITT analysis set included all participants who had a baseline measurement for the efficacy variable and did not use anti-malaria treatment after study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg</title>
            <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg</title>
            <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</title>
            <description>Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</title>
            <description>Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</title>
            <description>Participants aged 13-24 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
          </group>
          <group group_id="O9">
            <title>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</title>
            <description>Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Egg Reduction Rate (Percent)</title>
          <description>Percent reduction in egg count was calculated as geometric mean egg count at post-treatment minus geometric mean egg count at baseline (before treatment) divided by geometric mean egg count at baseline.</description>
          <population>mITT analysis set included all participants who had a baseline measurement for the efficacy variable and did not use anti-malaria treatment after study treatment.</population>
          <units>percent reduction in egg count</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" lower_limit="89.8" upper_limit="99.4"/>
                    <measurement group_id="O2" value="83.3" lower_limit="74.7" upper_limit="91.9"/>
                    <measurement group_id="O3" value="88.6" lower_limit="81.8" upper_limit="95.4"/>
                    <measurement group_id="O4" value="88.6" lower_limit="82.2" upper_limit="94.9"/>
                    <measurement group_id="O5" value="88.3" lower_limit="81.3" upper_limit="95.3"/>
                    <measurement group_id="O6" value="92.3" lower_limit="86.4" upper_limit="98.1"/>
                    <measurement group_id="O7" value="94.1" lower_limit="88.6" upper_limit="99.6"/>
                    <measurement group_id="O8" value="97.7" lower_limit="92.9" upper_limit="100.0"/>
                    <measurement group_id="O9" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Cure Determined by Point-of-Care Circulating Cathodic Antigen (POC-CCA) Test</title>
        <description>Clinical Cure defined as no parasite eggs in the stools as assessed by the commercially available POC-CCA assay for S. mansoni. Number of participants with clinical cure were reported.</description>
        <time_frame>Day 2, Day 8 and 14-21 days post treatment</time_frame>
        <population>mITT analysis set included all participants who had a baseline measurement for the efficacy variable and did not use anti-malaria treatment after study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg</title>
            <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg</title>
            <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</title>
            <description>Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</title>
            <description>Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</title>
            <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</title>
            <description>Participants aged 13-24 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
          </group>
          <group group_id="O9">
            <title>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</title>
            <description>Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Cure Determined by Point-of-Care Circulating Cathodic Antigen (POC-CCA) Test</title>
          <description>Clinical Cure defined as no parasite eggs in the stools as assessed by the commercially available POC-CCA assay for S. mansoni. Number of participants with clinical cure were reported.</description>
          <population>mITT analysis set included all participants who had a baseline measurement for the efficacy variable and did not use anti-malaria treatment after study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-21 days post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Day 21</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg</title>
          <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg</title>
          <description>Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg</title>
          <description>Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg</title>
          <description>Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1, Cohort 5: Levo Praziquantel 30 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1, Cohort 6: Levo Praziquantel 45 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Part 1, Cohort 7: Levo Praziquantel 60 mg/kg</title>
          <description>Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Part 2, Cohort 8: Levo Praziquantel 50 mg/kg</title>
          <description>Participants aged 13-24 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
        </group>
        <group group_id="E9">
          <title>Part 2, Cohort 9: Levo Praziquantel 50 mg/kg</title>
          <description>Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Communication Center</name_or_title>
      <organization>Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@emdgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

